

## **EDIT IMPLEMENTATION SCHEDULE**

Clinical edits are designed to enhance patient care and optimize the use of program funds through the therapeutically prudent use of pharmaceuticals. Point-of-service pharmacy claims will be routed through an automated computer system to apply edits specifically designed to assure effective drug utilization. The edits are based on evidence-based clinical criteria and available nationally recognized peer-reviewed information. Through the clinical edit process, therapy will automatically and transparently be approved for those patients who meet any of the system approval criteria. For those participants who do not meet the system approval criteria, therapy will require a call to the MO HealthNet Drug Prior Authorization hotline at **(800) 392-8030** to initiate a review and potentially authorize claims. MO HealthNet will use the clinical edit program software to implement a state specific Preferred Drug List (PDL).

| <b>Scheduled Therapeutic Class/Drug Product Edits</b>                                      | <b>Effective Date</b> |
|--------------------------------------------------------------------------------------------|-----------------------|
| Fabry Disease Clinical Edit (Annual)                                                       | 08/03/2023            |
| Givlaari Clinical Edit (Annual)                                                            | 08/03/2023            |
| Hemgenix Clinical Edit (NEW)                                                               | 08/03/2023            |
| Imcivree Clinical Edit (Annual)                                                            | 08/03/2023            |
| Isturisa Clinical Edit (Annual)                                                            | 08/03/2023            |
| Nulibry Clinical Edit (Annual)                                                             | 08/03/2023            |
| Oxervate Clinical Edit (Annual)                                                            | 08/03/2023            |
| Oxlumo Clinical Edit (Annual)                                                              | 08/03/2023            |
| Scenesse Clinical Edit (Annual)                                                            | 08/03/2023            |
| Tavneos Clinical Edit (Annual)                                                             | 08/03/2023            |
| Tzield Clinical Edit (NEW)                                                                 | 08/03/2023            |
| Voxzogo Clinical Edit (Annual)                                                             | 08/03/2023            |
| Zokinvy Clinical Edit (Annual)                                                             | 08/03/2023            |
| Acne & Rosacea – Select Topical Agents Step Therapy Edit (Annual)                          | 07/27/2023            |
| Megestrol Acetate Clinical Edit (Annual)                                                   | 07/27/2023            |
| Sickle Cell Disease Clinical Edit (Annual)                                                 | 07/27/2023            |
| Spravato Clinical Edit (Annual)                                                            | 07/20/2023            |
| Systemic Antifungals Clinical Edit (Annual)                                                | 07/20/2023            |
| Zulresso Clinical Edit (Annual)                                                            | 07/20/2023            |
| Actinic Keratosis Agents, Topical PDL Edit (Annual)                                        | 07/06/2023            |
| Androgenic Agents PDL Edit (Annual)                                                        | 07/06/2023            |
| Antibiotics, Inhaled PDL Edit (Annual)                                                     | 07/06/2023            |
| Anticholinergics, LABA Combinations PDL Edit (Annual)                                      | 07/06/2023            |
| Anticholinergics, LABAs/ICS Combinations and PDE4 Inhibitors PDL Edit (Annual)             | 07/06/2023            |
| Anticholinergics, Long Acting Inhaled PDL Edit (Annual)                                    | 07/06/2023            |
| Anticholinergics, Short Acting and Combinations Inhaled PDL Edit (Annual)                  | 07/06/2023            |
| Antifungals, Oral PDL Edit (Annual)                                                        | 07/06/2023            |
| Antifungals, Topical PDL Edit (Annual)                                                     | 07/06/2023            |
| Antihistamines & Antihistamine/Decongestant Combinations, 2nd Generation PDL Edit (Annual) | 07/06/2023            |
| Antihistamines, Intranasal PDL Edit (Annual)                                               | 07/06/2023            |
| Antihistamines, Ophthalmic PDL Edit (Annual)                                               | 07/06/2023            |
| Antiparasitics, Topical PDL Edit (Annual)                                                  | 07/06/2023            |
| Antivirals, Herpes Oral PDL Edit (Annual)                                                  | 07/06/2023            |
| Antivirals, Topical PDL Edit (Annual)                                                      | 07/06/2023            |
| Benzoyl Peroxide/Antibiotic Combinations PDL Edit (Annual)                                 | 07/06/2023            |
| Beta Adrenergic Agents, Long Acting PDL Edit (Annual)                                      | 07/06/2023            |
| Beta Adrenergic Agents, Nebulized PDL Edit (Annual)                                        | 07/06/2023            |
| Beta Adrenergic Agents, Short Acting PDL Edit (Annual)                                     | 07/06/2023            |
| Corticosteroids & Rhinitis Agents, Intranasal PDL Edit (Annual)                            | 07/06/2023            |
| Corticosteroids, Ophthalmic Soft PDL Edit (Annual)                                         | 07/06/2023            |
| Corticosteroids, Oral Inhaled PDL Edit (Annual)                                            | 07/06/2023            |

| Scheduled Therapeutic Class/Drug Product Edits                                               | Effective Date |
|----------------------------------------------------------------------------------------------|----------------|
| Corticosteroids, Topical PDL Edit (Annual)                                                   | 07/06/2023     |
| Cough/Cold Preparations PDL Edit (Annual)                                                    | 07/06/2023     |
| Epinephrine Agents, Self-Injectable PDL Edit (Annual)                                        | 07/06/2023     |
| Fluoroquinolones, Ophthalmic PDL Edit (Annual)                                               | 07/06/2023     |
| Fluoroquinolones, Otic PDL Edit (Annual)                                                     | 07/06/2023     |
| Glaucoma Agents PDL Edit (Annual)                                                            | 07/06/2023     |
| Hepatitis C Agents PDL Edit (Annual)                                                         | 07/06/2023     |
| Inflammatory Bowel Disease Agents, Oral PDL Edit (Annual)                                    | 07/06/2023     |
| Inflammatory Bowel Disease Agents, Rectal PDL Edit (Annual)                                  | 07/06/2023     |
| Leukotriene Receptor Modifiers PDL Edit (Annual)                                             | 07/06/2023     |
| Mast Cell Stabilizers, Ophthalmic PDL Edit (Annual)                                          | 07/06/2023     |
| NSAIDs, Ophthalmic PDL Edit (Annual)                                                         | 07/06/2023     |
| Pancreatic Enzymes PDL Edit (Annual)                                                         | 07/06/2023     |
| Retinoids, Topical PDL Edit (Annual)                                                         | 07/06/2023     |
| HBV Nucleotide Analog Reverse Transcriptase Inhibitors Fiscal Edit (Annual)                  | 05/11/2023     |
| Non-Oral Contraceptives Fiscal Edit (Annual)                                                 | 05/11/2023     |
| Oxazolidinone Fiscal Edit (Annual)                                                           | 05/11/2023     |
| Selzentry Clinical Edit (Annual)                                                             | 05/11/2023     |
| Aduhelm Clinical Edit (Annual)                                                               | 05/04/2023     |
| Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators Clinical Edit (Annual) | 05/04/2023     |
| Empaveli Clinical Edit (Annual)                                                              | 05/04/2023     |
| Pompe Disease Clinical Edit (Annual)                                                         | 05/04/2023     |
| Skysona Clinical Edit (NEW)                                                                  | 05/04/2023     |
| Xenpozyme Clinical Edit (NEW)                                                                | 05/04/2023     |
| Ztalmy Clinical Edit (NEW)                                                                   | 05/04/2023     |
| Zynteglo Clinical Edit (NEW)                                                                 | 05/04/2023     |
| Camzyos Clinical Edit (NEW)                                                                  | 04/27/2023     |
| Corlanor Clinical Edit (Annual)                                                              | 04/27/2023     |
| Kerendia Clinical Edit (Annual)                                                              | 04/27/2023     |
| Verquvo Clinical Edit (Annual)                                                               | 04/27/2023     |
| Benzodiazepine, Select Oral Clinical Edit (Annual)                                           | 04/20/2023     |
| Butalbital Combinations without Codeine Clinical Edit (Annual)                               | 04/20/2023     |
| High Risk Therapies Clinical Edit (Annual)                                                   | 04/20/2023     |
| Morphine Milligram Equivalent Accumulation Clinical Edit (Annual)                            | 04/20/2023     |
| Opioids, Short Acting Clinical Edit (Annual)                                                 | 04/20/2023     |
| Transmucosal Immediate Release Fentanyl (TIRF) Clinical Edit (Annual)                        | 04/20/2023     |
| Antipsychotics - 1st Generation (Typical) Clinical Edit (Annual)                             | 04/06/2023     |
| Antipsychotics - 2nd Generation (Atypical) Depot Agents Resource List (Annual)               | 04/06/2023     |
| Antipsychotics - 2nd Generation (Atypical) Oral & Transdermal Agents Resource List (Annual)  | 04/06/2023     |
| Alzheimer's Agents, AChEIs and NMDA Receptor Antagonists & Combinations PDL Edit (Annual)    | 04/06/2023     |
| Antiandrogenic Agents PDL Edit (Annual)                                                      | 04/06/2023     |
| Anticonvulsants, Dravet Syndrome PDL Edit (Annual)                                           | 04/06/2023     |
| Antiemetics, 5-HT3 and NK1 Injectables PDL Edit (Annual)                                     | 04/06/2023     |
| Antiemetics, 5-HT3, NK1 and Other Select Non-Injectables PDL Edit (Annual)                   | 04/06/2023     |
| Anti-Migraine, Alternative Oral Agents PDL Edit (Annual)                                     | 04/06/2023     |
| Anti-Migraine, Serotonin (5-HT1) Receptor Agonists PDL Edit (Annual)                         | 04/06/2023     |
| Anti-Parkinsonism, MAO-B Inhibitors PDL Edit (Annual)                                        | 04/06/2023     |
| Anti-Parkinsonism, Non-Ergot Dopamine Agonists PDL Edit (Annual)                             | 04/06/2023     |
| Antiretroviral Therapy (ART) PDL Edit (Annual)                                               | 04/06/2023     |
| Calcitonin Gene-Related Peptide (CGRP) Inhibitors PDL Edit (Annual)                          | 04/06/2023     |
| Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors PDL Edit (Annual)                               | 04/06/2023     |

| Scheduled Therapeutic Class/Drug Product Edits                                                            | Effective Date |
|-----------------------------------------------------------------------------------------------------------|----------------|
| Fibromyalgia Agents PDL Edit (Annual)                                                                     | 04/06/2023     |
| GI Motility Agents, Chronic PDL Edit (Annual)                                                             | 04/06/2023     |
| Glucagon Agents PDL Edit (Annual)                                                                         | 04/06/2023     |
| Hereditary Angioedema Agents PDL Edit (Annual)                                                            | 04/06/2023     |
| Mitogen-activated Extracellular Kinase Inhibitors (MEKi) & B-raf Kinase Inhibitors (BRAFi) PDL Edit (NEW) | 04/06/2023     |
| Neuropathic Pain Agents PDL Edit (Annual)                                                                 | 04/06/2023     |
| NSAIDs PDL Edit (Annual)                                                                                  | 04/06/2023     |
| Opioid & Select Alcohol Dependence Agents PDL Edit (Annual)                                               | 04/06/2023     |
| Opioid Emergency Reversal Agents PDL Edit (Annual)                                                        | 04/06/2023     |
| Opioids, Long Acting PDL Edit (Annual)                                                                    | 04/06/2023     |
| Sedative Hypnotics PDL Edit (Annual)                                                                      | 04/06/2023     |
| Skeletal Muscle Relaxants PDL Edit (Annual)                                                               | 04/06/2023     |
| Somatostatin Analogs PDL Edit (Annual)                                                                    | 04/06/2023     |
| Tramadol-Like Agents PDL Edit (Annual)                                                                    | 04/06/2023     |
| Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors PDL Edit (Annual)                                    | 04/06/2023     |
| ACE-Inhibitors/Calcium Channel Blocker Combinations PDL Edit (Annual)                                     | 01/12/2023     |
| ADHD, Amphetamines, Long-Acting PDL Edit (Annual)                                                         | 01/12/2023     |
| ADHD, Amphetamines, Short-Acting PDL Edit (Annual)                                                        | 01/12/2023     |
| ADHD, Methylphenidate, Long-Acting PDL Edit (Annual)                                                      | 01/12/2023     |
| ADHD, Methylphenidate, Short-Acting PDL Edit (Annual)                                                     | 01/12/2023     |
| ADHD, Non-Stimulants PDL Edit (Annual)                                                                    | 01/12/2023     |
| Alpelisib Clinical Edit (NEW)                                                                             | 01/12/2023     |
| Alpha-Glucosidase Inhibitors PDL Edit (Annual)                                                            | 01/12/2023     |
| Amylin Analogs PDL Edit (Annual)                                                                          | 01/12/2023     |
| Antibiotics, GI Oral PDL Edit (Annual)                                                                    | 01/12/2023     |
| Antibiotics, Mupirocin Topical PDL Edit (Annual)                                                          | 01/12/2023     |
| Antibiotics, Vaginal PDL Edit (Annual)                                                                    | 01/12/2023     |
| Anticoagulants PDL Edit (Annual)                                                                          | 01/12/2023     |
| Anticonvulsants, Rescue Agents PDL Edit (Annual)                                                          | 01/12/2023     |
| Antihyperuricemic Agents PDL Edit (Annual)                                                                | 01/12/2023     |
| Antiplatelets PDL Edit (Annual)                                                                           | 01/12/2023     |
| ARBs and ARBs/Diuretic Combinations PDL Edit (Annual)                                                     | 01/12/2023     |
| ARBs/ Calcium Channel Blocker Combinations PDL Edit (Annual)                                              | 01/12/2023     |
| Benign Prostatic Hyperplasia (BPH) Agents PDL Edit (Annual)                                               | 01/12/2023     |
| Beta Blockers & Beta Blockers/Diuretic Combinations PDL Edit (Annual)                                     | 01/12/2023     |
| Biguanides & Combinations PDL Edit (Annual)                                                               | 01/12/2023     |
| Bile Salt Agents PDL Edit (Annual)                                                                        | 01/12/2023     |
| Bone Ossification Agents PDL Edit (Annual)                                                                | 01/12/2023     |
| Calcium Channel Blockers, Dihydropyridines PDL Edit (Annual)                                              | 01/12/2023     |
| Calcium Channel Blockers, Non-Dihydropyridines PDL Edit (Annual)                                          | 01/12/2023     |
| Carbamoyl Phosphate Synthetase 1 Activators PDL Edit (NEW)                                                | 01/12/2023     |
| Cephalosporin Agents PDL Edit (Annual)                                                                    | 01/12/2023     |
| Colony Stimulating Factors PDL Edit (Annual)                                                              | 01/12/2023     |
| Cyproyin-Associated Periodic Syndrome (CAPS) Agents PDL Edit (Annual)                                     | 01/12/2023     |
| Direct Renin Inhibitors & Combinations PDL Edit (Annual)                                                  | 01/12/2023     |
| DPP-IV Inhibitors & Combinations PDL Edit (Annual)                                                        | 01/12/2023     |
| Dry Eye Disease Agents PDL Edit (Annual)                                                                  | 01/12/2023     |
| Electrolyte Depleting Agents, Phosphate Lowering PDL Edit (Annual)                                        | 01/12/2023     |
| Electrolyte Depleting Agents, Potassium Lowering PDL Edit (Annual)                                        | 01/12/2023     |
| Entresto Clinical Edit (Annual)                                                                           | 01/12/2023     |
| Erythropoiesis Stimulating Agents PDL Edit (Annual)                                                       | 01/12/2023     |
| Fluoroquinolone Agents, Oral PDL Edit (Annual)                                                            | 01/12/2023     |

| <b>Scheduled Therapeutic Class/Drug Product Edits</b>                                                                 | <b>Effective Date</b> |
|-----------------------------------------------------------------------------------------------------------------------|-----------------------|
| Glucagon-Like Peptide -1 (GLP-1) Receptor Agonists & Combination Agents PDL Edit (Annual)                             | 01/12/2023            |
| Growth Hormone & Growth Hormone Releasing Factors, Select Agents PDL Edit (Annual)                                    | 01/12/2023            |
| Growth Hormone Agents, Somatropin PDL Edit (Annual)                                                                   | 01/12/2023            |
| Homozygous Familial Hypercholesterolemia (HoFH) Agents PDL Edit (Annual)                                              | 01/12/2023            |
| Insulin, Long Acting PDL Edit (Annual)                                                                                | 01/12/2023            |
| Insulin, Mixed PDL Edit (Annual)                                                                                      | 01/12/2023            |
| Insulin, Non-Analogs PDL Edit (Annual)                                                                                | 01/12/2023            |
| Insulin, Rapid Acting PDL Edit (Annual)                                                                               | 01/12/2023            |
| Luteinizing Hormone Releasing Hormone (LHRH)/Gonadotropin Releasing Hormone (GnRH) Agents, Non-Oral PDL Edit (Annual) | 01/12/2023            |
| Luteinizing Hormone Releasing Hormone (LHRH)/Gonadotropin Releasing Hormone (GnRH) Agents, Oral PDL Edit (Annual)     | 01/12/2023            |
| Macrolides PDL Edit (Annual)                                                                                          | 01/12/2023            |
| Meglitinides PDL Edit (Annual)                                                                                        | 01/12/2023            |
| Methotrexate Agents PDL Edit (Annual)                                                                                 | 01/12/2023            |
| Multiple Sclerosis Agents, Injectable PDL Edit (Annual)                                                               | 01/12/2023            |
| Multiple Sclerosis Agents, Oral PDL Edit (Annual)                                                                     | 01/12/2023            |
| Niacin Derivatives PDL Edit (Annual)                                                                                  | 01/12/2023            |
| Penicillin Agents PDL Edit (Annual)                                                                                   | 01/12/2023            |
| Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) Binders PDL Edit (Annual)                                       | 01/12/2023            |
| Proton Pump Inhibitors PDL Edit (Annual)                                                                              | 01/12/2023            |
| Pulmonary Arterial Hypertension (PAH) Agents, Endothelin Receptor Antagonists (ETRA) PDL Edit (Annual)                | 01/12/2023            |
| Pulmonary Arterial Hypertension (PAH) Agents, PDE5-Inhibitors and SGC Stimulators PDL Edit (Annual)                   | 01/12/2023            |
| Pulmonary Arterial Hypertension (PAH) Agents, Prostacyclins, Inhaled PDL Edit (Annual)                                | 01/12/2023            |
| Pulmonary Arterial Hypertension (PAH) Agents, Prostacyclins, Injectable PDL Edit (Annual)                             | 01/12/2023            |
| Pulmonary Arterial Hypertension (PAH) Agents, Prostacyclins, Oral PDL Edit (Annual)                                   | 01/12/2023            |
| Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors & Combination Agents PDL Edit (Annual)                             | 01/12/2023            |
| Spinal Muscular Atrophy (SMA) Clinical Edit (Annual)                                                                  | 01/12/2023            |
| Statins (HMG Co-A Reductase Inhibitors) & Combinations PDL Edit (Annual)                                              | 01/12/2023            |
| Sulfonylureas, Second Generation PDL Edit (Annual)                                                                    | 01/12/2023            |
| Sympatholytic Agents PDL Edit (Annual)                                                                                | 01/12/2023            |
| Targeted Immune Modulators, IL17 Antibody/IL17 Receptor Antagonists PDL Edit (Annual)                                 | 01/12/2023            |
| Targeted Immune Modulators, IL23 Inhibitors and IL23/IL12 Inhibitors PDL Edit (Annual)                                | 01/12/2023            |
| Targeted Immune Modulators, IL6 Receptor Inhibitors PDL Edit (Annual)                                                 | 01/12/2023            |
| Targeted Immune Modulators, Janus Kinase (JAK) Inhibitors PDL Edit (Annual)                                           | 01/12/2023            |
| Targeted Immune Modulators, Misc. Allergy and Asthma Related Monoclonal Antibodies PDL Edit (Annual)                  | 01/12/2023            |
| Targeted Immune Modulators, Select Agents PDL Edit (Annual)                                                           | 01/12/2023            |
| Targeted Immune Modulators, TNF Inhibitors PDL Edit (Annual)                                                          | 01/12/2023            |
| Tetracycline Agents PDL Edit (Annual)                                                                                 | 01/12/2023            |
| Thiazolidinediones & Combinations PDL Edit (Annual)                                                                   | 01/12/2023            |
| Thrombocytopenia Agents PDL Edit (Annual)                                                                             | 01/12/2023            |
| Transthyretin-Mediated Amyloidosis (ATTR) Clinical Edit (Annual)                                                      | 01/12/2023            |
| Triglyceride Lowering Agents PDL Edit (Annual)                                                                        | 01/12/2023            |
| Urinary Tract Antispasmodics PDL Edit (Annual)                                                                        | 01/12/2023            |
| Ampyra Clinical Edit (Annual)                                                                                         | 10/20/2022            |
| Besremi Clinical Edit (NEW)                                                                                           | 10/20/2022            |
| Botulinum Toxin Clinical Edit (Annual)                                                                                | 10/20/2022            |

| <b>Scheduled Therapeutic Class/Drug Product Edits</b>                                        | <b>Effective Date</b> |
|----------------------------------------------------------------------------------------------|-----------------------|
| CAR-T Cell Therapy Clinical Edit (Annual)                                                    | 10/20/2022            |
| Crysvita Clinical Edit (Annual)                                                              | 10/20/2022            |
| Duchenne Muscular Dystrophy (DMD) Clinical Edit (Annual)                                     | 10/20/2022            |
| Emsam Clinical Edit (Annual)                                                                 | 10/20/2022            |
| Enjaymo Clinical Edit (NEW)                                                                  | 10/20/2022            |
| Enzyme Deficiency, Select Agents Clinical Edit (NEW)                                         | 10/20/2022            |
| Gamifant Clinical Edit (Annual)                                                              | 10/20/2022            |
| Immunoglobulins (IVIG and SCIG) Clinical Edit (Annual)                                       | 10/20/2022            |
| Iron – Injectable Step Therapy Edit (Annual)                                                 | 10/20/2022            |
| Koselugo Clinical Edit (Annual)                                                              | 10/20/2022            |
| Lambert-Eaton Myasthenic Syndrome (LEMS) Clinical Edit (Annual)                              | 10/20/2022            |
| Luxturna Clinical Edit (Annual)                                                              | 10/20/2022            |
| Manufacturers Requiring Prior Authorization Fiscal Edit (NEW)                                | 10/20/2022            |
| Narcolepsy Inhibitors Clinical Edit (Annual)                                                 | 10/20/2022            |
| Neuromyelitis Optica Spectrum Disorder (NMOSD) Clinical Edit (Annual)                        | 10/20/2022            |
| Nuedexta Clinical Edit (Annual)                                                              | 10/20/2022            |
| Oxandrin Clinical Edit (Annual)                                                              | 10/20/2022            |
| Palforzia Clinical Edit (NEW)                                                                | 10/20/2022            |
| Palynziq Clinical Edit (Annual)                                                              | 10/20/2022            |
| Parathyroid Hormone & Bone Resorption Suppression Related Agents Clinical Edit (Annual)      | 10/20/2022            |
| Psychotropic Medications Polypharmacy Clinical Edit (Annual)                                 | 10/20/2022            |
| Ranexa Clinical Edit (Annual)                                                                | 10/20/2022            |
| Reblozyl Clinical Edit (Annual)                                                              | 10/20/2022            |
| Selective Serotonin Reuptake Inhibitors (SSRI) Step Therapy Edit (Annual)                    | 10/20/2022            |
| Serotonin and Norepinephrine Reuptake Inhibitors (SNRI) Clinical Edit (Annual)               | 10/20/2022            |
| Targeted Immune Modulators, Small Molecule Janus Kinase (JAK) Inhibitors Clinical Edit (NEW) | 10/20/2022            |
| Tepezza Clinical Edit (Annual)                                                               | 10/20/2022            |
| Tolvaptan Clinical Edit (Annual)                                                             | 10/20/2022            |
| Transthyretin-Mediated Amyloidosis (ATTR) Clinical Edit (Annual)                             | 10/20/2022            |
| Vyvgart Clinical Edit (NEW)                                                                  | 10/20/2022            |
| Xcopri Clinical Edit (Annual)                                                                | 10/20/2022            |
| Zometa Clinical Edit (Annual)                                                                | 10/20/2022            |
| Synagis Clinical Edit (Annual)                                                               | 10/06/2022            |
| Short Acting Beta Adrenergic (SABA) Agents – Inhalers Excessive Therapy Clinical Edit        | 08/18/2022            |
| Short Acting Beta Adrenergic (SABA) Agents – Nebulized Excessive Therapy Clinical Edit       | 08/18/2022            |
| C5 Complement Inhibitors Clinical Edit (NEW)                                                 | 08/04/2022            |
| Fabry Disease Clinical Edit (Annual)                                                         | 08/04/2022            |
| Givlaari Clinical Edit (Annual)                                                              | 08/04/2022            |
| Imcivree Clinical Edit (Annual)                                                              | 08/04/2022            |
| Isturisa Clinical Edit (Annual)                                                              | 08/04/2022            |
| Nulibry Clinical Edit (Annual)                                                               | 08/04/2022            |
| Oxervate Clinical Edit (Annual)                                                              | 08/04/2022            |
| Oxlumo Clinical Edit (Annual)                                                                | 08/04/2022            |
| Scenesse Clinical Edit (NEW)                                                                 | 08/04/2022            |
| Systemic Antifungals Clinical Edit (Annual)                                                  | 08/04/2022            |
| Tavneos Clinical Edit (NEW)                                                                  | 08/04/2022            |
| Voxzogo Clinical Edit (NEW)                                                                  | 08/04/2022            |
| Zokinvy Clinical Edit (Annual)                                                               | 08/04/2022            |
| Acne & Rosacea – Select Topical Agents Step Therapy Edit (Annual)                            | 07/28/2022            |
| Sickle Cell Disease Clinical Edit (Annual)                                                   | 07/28/2022            |
| Zulresso Clinical Edit (Annual)                                                              | 07/28/2022            |

| <b>Scheduled Therapeutic Class/Drug Product Edits</b>                                        | <b>Effective Date</b> |
|----------------------------------------------------------------------------------------------|-----------------------|
| Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators Clinical Edit (Annual) | 07/21/2022            |
| Megestrol Acetate Clinical Edit (Annual)                                                     | 07/21/2022            |
| Spravato Clinical Edit (Annual)                                                              | 07/21/2022            |
| Actinic Keratosis Agents, Topical PDL Edit (Annual)                                          | 07/07/2022            |
| Androgenic Agents PDL Edit (Annual)                                                          | 07/07/2022            |
| Antibiotics, Inhaled PDL Edit (Annual)                                                       | 07/07/2022            |
| Anticholinergics, LABA Combinations PDL Edit (Annual)                                        | 07/07/2022            |
| Anticholinergics, LABAs/ICS Combinations and PDE4 Inhibitors PDL Edit (Annual)               | 07/07/2022            |
| Anticholinergics, Long Acting Inhaled PDL Edit (Annual)                                      | 07/07/2022            |
| Anticholinergics, Short Acting and Combinations Inhaled PDL Edit (Annual)                    | 07/07/2022            |
| Antifungals, Oral PDL Edit (Annual)                                                          | 07/07/2022            |
| Antifungals, Topical PDL Edit (Annual)                                                       | 07/07/2022            |
| Antihistamines & Antihistamines/Decongestant Combinations, 2nd Generation PDL Edit (Annual)  | 07/07/2022            |
| Antihistamines, Intranasal PDL Edit (Annual)                                                 | 07/07/2022            |
| Antihistamines, Ophthalmic PDL Edit (Annual)                                                 | 07/07/2022            |
| Antiparasitics, Topical PDL Edit (Annual)                                                    | 07/07/2022            |
| Antivirals, Herpes Oral PDL Edit (Annual)                                                    | 07/07/2022            |
| Antivirals, Topical PDL Edit (Annual)                                                        | 07/07/2022            |
| Atopic Dermatitis Agents, Immunomodulators PDL Edit (Annual)                                 | 07/07/2022            |
| Benzoyl Peroxide/Antibiotic Combinations PDL Edit (Annual)                                   | 07/07/2022            |
| Beta Adrenergic Agents, Long Acting PDL Edit (Annual)                                        | 07/07/2022            |
| Beta Adrenergic Agents, Nebulized PDL Edit (Annual)                                          | 07/07/2022            |
| Beta Adrenergic Agents, Short Acting PDL Edit (Annual)                                       | 07/07/2022            |
| Corticosteroids and Rhinitis Agents, Intranasal PDL Edit (Annual)                            | 07/07/2022            |
| Corticosteroids, Ophthalmic Soft PDL Edit (Annual)                                           | 07/07/2022            |
| Corticosteroids, Oral Inhaled PDL Edit (Annual)                                              | 07/07/2022            |
| Corticosteroids, Topical PDL Edit (Annual)                                                   | 07/07/2022            |
| Cough/Cold Preparations PDL Edit (Annual)                                                    | 07/07/2022            |
| Epinephrine Agents, Self-Injectable PDL Edit (Annual)                                        | 07/07/2022            |
| Fluoroquinolones, Ophthalmic PDL Edit (Annual)                                               | 07/07/2022            |
| Fluoroquinolones, Otic PDL Edit (Annual)                                                     | 07/07/2022            |
| Glaucoma Agents PDL Edit (Annual)                                                            | 07/07/2022            |
| Hepatitis C Agents PDL Edit (Annual)                                                         | 07/07/2022            |
| Leukotriene Receptor Modifiers PDL Edit (Annual)                                             | 07/07/2022            |
| Mast Cell Stabilizers, Ophthalmic PDL Edit (Annual)                                          | 07/07/2022            |
| NSAIDs, Ophthalmic PDL Edit (Annual)                                                         | 07/07/2022            |
| Pancreatic Enzymes PDL Edit (Annual)                                                         | 07/07/2022            |
| Psoriasis Agents, Oral PDL Edit (Annual)                                                     | 07/07/2022            |
| Psoriasis Agents, Topical PDL Edit (Annual)                                                  | 07/07/2022            |
| Respiratory Monoclonal Antibodies (RMA) PDL Edit (Annual)                                    | 07/07/2022            |
| Retinoids, Topical PDL Edit (Annual)                                                         | 07/07/2022            |
| Ulcerative Colitis Agents, Oral PDL Edit (Annual)                                            | 07/07/2022            |
| Ulcerative Colitis Agents, Rectal PDL Edit (Annual)                                          | 07/07/2022            |